TME Pharma N.V. (ALTME) Stock Statistics & Valuation Metrics

TME Pharma N.V. has a market cap or net worth of €6.94M. The enterprise value is €7.83M.

TME Pharma N.V. has 94,188,980 shares outstanding. The number of shares has decreased by -2.65% in one year.

TME Pharma N.V.’s return on equity (ROE) is 2.08 and return on invested capital (ROIC) is -270.01%.

The current PE Ratio of TME Pharma N.V. is ―. TME Pharma N.V.’s PEG ratio is 0.02.

In the last 12 months, TME Pharma N.V. had revenue of 0.00 and earned -3.29M in profits. Earnings per share was -0.03.

In the last 12 months, operating cash flow was -3.42M and capital expenditures 0.00, giving a free cash flow of -3.42M billion.

TME Pharma N.V. pays an annual dividend of ―, resulting in a dividend yield of ―

TME Pharma N.V. upcoming earnings date is Oct 29, 2026, Before Open (Confirmed).

TME Pharma N.V. as a current ratio of 0.57, with Debt / Equity ratio of -168.21%

In the past 12 months, TME Pharma N.V. has paid 0.00 in taxes.

TME Pharma N.V. EV to EBITDA ratio is -2.34, with an EV/FCF ratio of -1.98.

TME Pharma N.V. has €2.02M in cash and marketable securities with €2.66M in debt, giving a net cash position of -€640.00K billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for TME Pharma N.V. is ―, which is 11.43% higher than the current price. The consensus rating is ―